VAXXON® SRP® E. COLI-SE​

KEEP YOUR BIRDS ALIVE AND WELL WITH THE
FIRST AND ONLY INACTIVATED E. COLI VACCINE

VAXXON® SRP® E. COLI-SE
THE FIRST AND ONLY INACTIVATED E. COLI VACCINE

For MORE EGGS per hen housed by increasing livability and decreasing incidence of E. coli peritonitis (1)

DEAD BIRDS DON’T LAY EGGS:

Improve bird health and welfare, while maximizing genetic potential with E. coli and Salmonella protection using SRP technology.

REDUCED E. COLI AND SALMONELLA:

Zero mortality observed in vaccinated groups of all challenge studies. Effective against colonization of E. coli in the reproductive tract, internal organs and air sacs (1). Effective against SE colonization of the reproductive tract, internal organs and intestinal tract (1).

BROAD PROTECTION:

By combining E. coli and Salmonella vaccines into one dose, you get 2X the protection for 1X the labor.

SAFETY FIRST:

SRP vaccines are highly purified proteins, which often result in less flock setback and less tissue reaction than whole cell bacterins.

Efficacy:

Effective against E. coli challenge (1)

This product has been shown to be effective against mortality caused by E. coli

Improved overall livability of vaccinated flock results in:

    • More eggs per hen-housed
    • Healthier birds result in better egg production
    • Help birds live to their genetic potential

This product has been shown to be effective against colonization of E. coli in the reproductive tract, internal organs and air sacs

    • Reduced incidence of peritonitis, air sacculitis, colibacillosis
    • Healthy reproductive tract leads to improved egg production
    • Reduced potential for secondary bacterial infections after viral infections or other stressors

E. coli Challenge Study: Mortality (1)

E. coli Challenge Study: Tissue Colonization

Effective against Salmonella Enteritidis (SE)

This product has been shown to be effective against SE colonization of the reproductive tract, internal organs, and intestinal tract (2)

    • Reduced probability of vertical transfer of SE to progeny
    • Reduced potential for horizontal spread and environmental contamination

Antibodies to SE SRP have been observed to last throughout lay period of broiler breeders (3)

    • SE SRP antibodies were detected in broiler breeders up to 62-weeks of age
    • SE SRP are passively transferred to progeny and detected till 14 days of age

SE Challenge Study: Tissue Colonization (2)

INDICATIONS: This product has been shown to be effective for the vaccination of healthy chickens 10 weeks of age or older against E. coli and Salmonella Enteritidis.  The duration of immunity has not been established.  For more information regarding efficacy and safety data, see productdata.aphis.usda.gov.

This product has been shown to be effective against mortality caused by E. coli and colonization of the reproductive tract, internal organs, and air sacs.  This product has been shown to be effective against Salmonella Enteritidis colonization of the reproductive tract, internal organs, and intestinal tract.

DIRECTIONS: Shake well before use. Administer 0.25 mL (1 dose) subcutaneously.  Revaccinate in 8-10 weeks.

CAUTIONS: Store at 35° to 46°F (2° to 8°C).  DO NOT FREEZE!  Use entire contents when first opened.  Do not vaccinate within 42 days of slaughter.  Contains gentamicin as a preservative.

Do not mix with other products.  For animal use only.  In case of human exposure, contact a physician.

Technical Inquiries: (888) 963-8471
For use by, or under, the supervision of a licensed veterinarian.

  1. Data on file, No. 1804, Epitopix LLC/Vaxxinova US, July 17, 2018.
  2. Data on file, Study No. 1821, Epitopix LLC/Vaxxinova US, February 22, 2019.
  3. Data on file, Study No. M2101, Epitopix, LLC/Vaxxinova US, xxxxxxxx, 2022
  4. Specter, S. Antibody Synthesis. In: xPharm: The Comprehensive Pharmacology Reference. Elsevier Press. pp. 1-6. 2007.
  5. Antigen properties, types and determinants of antigenicity. https://microbiologyinfo.com/antigen-properties-types-and-determinants-of-antigenicity/  Accessed 14 April 2020. 
  6. Immunogenicity of protein-based therapeutics. https://www.fda.gov/vaccines-blood-biologics/biologics-research-projects/immunogenicity-protein-based-therapeutics  Accessed April 14,  2020. 
  7. http://www2.hawaii.edu/~johnb/micro/medmicro/medmicro.9.html Accessed April 14, 2020.
  8. Data on file. Study no. M2103, Epitopix / Vaxxinova US, xxxxxxxx, 2022.
  9. Data on file. Study no. 1917, Epitopix, LLC/Vaxxinova US, January 8, 2021.

Inactivated E. coli-SE

Salmonella Entertidis

Vaxxon SRP Pasteurella

P. Mult SRP

Cholera Bacterin

Custom Vaccines

Whole-cell, SRP or both